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All mature blood cell types arise from a limited number of hematopoietic stem cells (HSCs). HSCs sustain hematopoiesis throughout the lifetime of an individual and any insult to them can lead to severe pathologies. Elucidating the molecular mechanisms that govern the maintenance and differentiation of HSCs is critical to understanding their role in hematological pathologies. In a search for novel regulators of HSCs, we selected SPARC (secreted protein acidic and rich in cysteine, also known as Osteonectin and BM40), because it was identified as one of the candidate regulators of HSCs by molecular profiling of differentiating hematopoietic cells in an in vitro model system. 1 Several lines of evidence have also indicated an important role for SPARC in hematopoiesis. In zebrafish, a knockdown of SPARC resulted in lower numbers of circulating blood cells in developing embryos. 2 In a murine model, SPARC deficiency resulted in thrombocytopenia and reduced erythroid colony formation. 3 In humans, SPARC is transcriptionally silenced in acute myeloid leukemia patients and in cell lines with mixed lineage leukemia rearrangements. 4 SPARC maps to the deleted region in 5q-myelodysplastic syndrome (MDS), an HSC disorder. With indications that SPARC may have a role in the hematopoietic system, we aimed to elucidate its role in the regulation of HSCs, as HSCs have not been characterized in the SPARC null mice.
SPARC is a glycoprotein that binds calcium and interacts with members of the extracellular matrix including collagens and thrombospodin. SPARC is expressed in a variety of tissues undergoing rapid turnover and is a major component of the bone. SPARC expression is associated with cell proliferation, migration, changes in morphology, matrix-remodeling and cell-cell interactions, although the precise function of the gene still remains unknown. 5 SPARC knockout mice (SPARC À / À ) are viable and fertile but display a number of abnormalities, including increased deposition of fat, highly contractile skin, alterations in wound healing and an altered response to tumor growth, most severe of which are osteopenia and early onset cataract. 6, 7 SPARC À / À mice generated previously by the targeted mutation of exon 6 that completely lacked SPARC mRNA and protein 6 were used in this study to carry out functional assays for HSCs.
Steady state hematopoiesis was unperturbed in SPARC À / À mice as seen by normal peripheral blood counts (Supplementary Table 1 ). A similar observation was made by Barlow et al. phenotypic analysis of the BM myeloerythroid compartment using a previously described fluorescence-activated cell sorting (FACS) strategy (Supplementary Figure 2) 9 showed no significant differences in the frequencies of HSCs or myeloerythroid progenitors (Supplementary Table 2 ). As defects in HSC regulation may not always be reflected in steady state hematopoiesis, 10 we tested if there was any functional impairment in SPARC À / À progenitors and HSCs. SPARC À / À hematopoietic progenitor cells showed normal proliferation and colony-forming ability in vitro, in methylcellulose-based cultures except for fewer burst forming units of the erythroid lineage (BFU-Es) (Supplementary Figure 3) , as also shown previously. 3 This defect in vitro did not translate to a defect in vivo as the mice were not anemic (Supplementary Table 1 ) and had normal erythroid progenitors in the BM (Supplementary Table 2 ).
We performed BM transplantations to analyze if BM cells lacking SPARC could reconstitute the hematopoietic system of lethally irradiated mice. Transplanted recipients, in a non-competitive setting, when followed for 16 weeks to assess donor contribution (schematic Figure 1a) , showed efficient, long-term multi-lineage hematopoietic reconstitution by SPARC À / À cells (Figure 1b) . When BM cells from primary recipients were transplanted into secondary recipients, the SPARC À / À cells continued to give rise to multilineage long-term hematopoiesis (Figure 1c) . SPARC À / À BM cells also performed similar to wild-type (WT) cells in competitive transplantations (Figures 1d and e) , strongly indicating that HSCs lacking SPARC had no impairment in their function. To quantify frequency of HSCs, we carried out limiting dilution competitive repopulation unit (CRU) assay. We found similar CRU frequencies in SPARC À / À mice compared with the WT (Figure 1f) .
We further tested if the hematopoietic system of SPARC À / À mice recovered normally from radiation or chemically induced hematopoietic stress. For radiation-induced stress, we followed hematopoietic recovery of mice subjected to sublethal doses of gamma irradiation. We used the chemical, phenylhydrazine to specifically stress the erythroid compartment as SPARC À / À cells gave fewer BFU-Es in in vitro colony-forming assay. We found no differences in the recovery of SPARC À / À mice compared with the controls in either radiation-induced or phenylhydrazineinduced stress of the hematopoietic system (Figures 2a and b) .
SPARC is a critical regulator of bone remodeling. 11 We therefore asked if the niche might be compromised in the absence of SPARC, by testing whether the niche could support normal hematopoiesis. We transplanted WT cells into lethally irradiated SPARC-deficient mice and found that the WT cells could give rise to long-term multi-lineage reconstitution (Figure 2c ). We found no skewing of myeloid and lymphoid lineages (Figure 2d ) and the peripheral blood counts of SPARC À / À recipients after 16 weeks of transplantation was found to be similar to WT recipients (Supplementary Table 3 ).
In humans, SPARC is expressed in BM CD34 þ cells, a compartment enriched in stem and progenitor cells. In 5q MDS patients, a deletion on chromosome 5 results in the loss of one copy of SPARC among other genes. Studies have shown that there is 70% downregulation in the expression of SPARC in the progenitor compartment. 3, 12 Lenalidomide is a drug that is used for the treatment of the disease. It inhibits growth of the malignant hematopoietic progenitors but its mechanism of action is not known. Although this drug has been shown to dramatically upregulate SPARC, evidence to support a direct role for this gene in the pathophysiology of the disease is limited. We examined the role of SPARC in hematopoiesis using a knockout mouse model and found it to be dispensable for normal hematopoiesis.
Steady state hematopoiesis was normal in SPARC À / À mice and transplantation assays showed that absence of SPARC did not affect the reconstitution ability of HSCs. We have also tested few other conditions of stress including gamma irradiation and phenylhydrazine. Our results show that SPARC does not have any cell intrinsic role in the regulation of hematopoiesis. There may be other complications of the hematopoietic system that have not been tested in this study, where SPARC may have a role. For instance, a complex situation could be the case of leukemias, which can result in more profound stress to the HSCs. It has been shown in cancers of other tissues that aberrant SPARC expression can lead to bad prognosis. 13 On the other hand, SPARC belongs to a family of proteins, few of which could potentially compensate for its function. Some members of the SPARC family have been shown to compensate for SPARC function in other organ systems. For example, SC-1 has a compensatory role for SPARC in angiogenesis related to foreign body response. Knockout mice for either SPARC or SC-1 show normal vessel densities on foreign body capsules but a double knockout of both the genes shows a significant increase in vessel density. 5 Our data from reverse transplantation experiments indicated that the lack of SPARC in the niche does not affect normal hematopoiesis from WT HSCs. SPARC may not be an important component of the hematopoietic niche even though its absence can lead to severe osteopenia. There are known molecules like Rac, signaling through which is required for normal bone development but dispensable for hematopoietic development.
14 Some components of the bone remodeling machinery like osteoclasts are also dispensable for hematopoiesis. 15 In summary, in vitro, lack of SPARC did not impair colonyforming capacity of BM hematopoietic cells, except for BFU-Es. In transplantation experiments SPARC À / À BM cells gave rise to long-term multi-lineage reconstitution. These cells competed normally with WT cells in competitive transplantation assays and responded as well as their WT counterparts to experimentally induced stress; indicating that SPARC is not essential for murine hematopoiesis. Furthermore, even in the absence of SPARC, the BM niche supported normal hematopoiesis assessed by transplantation of WT cells into SPARC À / À recipients. In conclusion, we tested the role of SPARC in murine HSC function and found that it is dispensable for both normal and stress hematopoiesis.
The mouse model used in our study had only the SPARC gene missing, unlike in 5q MDS where multiple genes are in the hemizygous state. It is possible that the change in dosage of multiple genes together can account for a strong disease-like phenotype. It is also possible that SPARC has more diverse functions in the human system. Therefore, before ruling out a role for SPARC in the disease, its role needs to be tested in human hematopoiesis to provide insights into the function of SPARC, if any, in the regulation of human hematopoietic stem and progenitor cells.
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu) High risks of familial chronic lymphatic leukemia for specific relatives: signposts for genetic discovery? Chronic lymphatic leukemia (CLL) presents a very high familial aggregation, 1,2 with a relative risk for first-degree relatives of CLL patients close to 8. In order to help understand the possible genetic mechanism for CLL inheritance, we conducted an in-depth investigation of the concordance in adult family members for CLL, focusing on the type of familial relationship and sex. Taking advantage of a large population-based database linked to information on family relationships, we examined how the type of kinship and sex affect the familial risk of adult CLL. We identified CLL cases diagnosed in Sweden over a period of almost 50 years, and compared the risk of CLL in their first-degree relatives to the risk in the first-degree relatives of matched individuals (controls) who were free of cancer.
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